



Clinical Treatment Scenarios: Vitiligo Pathogenesis and the Role of JAK Inhibition

Clinical Brief #1 – Therapy in Newly Diagnosed Patients

References

Tweet 2 References:

Grimes PE. Vitiligo: Management and prognosis. Updated April 2023. Accessed October 2, 2023.

<https://www.uptodate.com/contents/vitiligo-management-and-prognosis>

Kubelis-Lopez DE, Zapata-Salazar NA, Said-Fernandez SL, et al. Updates and new medical treatments for vitiligo (Review). *Exp Ther Med*. 2021;22(2):797. doi:10.3892/etm.2021.10229

Narayan VS, Uitentuis SE, Luiten RM, Bekkenk MW, Wolkerstorfer A. Patients' perspective on current treatments and demand for novel treatments in vitiligo. *J Eur Acad Dermatol Venereol*. 2021;35(3):744-748. doi:10.1111/jdv.16927

Searle T, Al-Niaimi F, Ali FR. Vitiligo: an update on systemic treatments. *Clin Exp Dermatol*. 2021;46(2):248-258. doi:10.1111/ced.14435

Additional References:

Hamzavi IH, Bibeau K, Grimes P, et al. Exploring the natural and treatment history of vitiligo: patient and healthcare professional perceptions from the global VALIANT study. *Br J Dermatol*. 2023;00:1-9. doi:10.1093/bjd/ljad245

OPZELURA™ (ruxolitinib) [prescribing information]. Incyte Corporation. Revised January 2023. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215309>

Rosmarin D, Liu J, Marwaha S, Lofland J, Piercy J, Anderson P. Abstract #246 Patient Burden of Nonsegmental Vitiligo: Perspectives From US Patients. Presented at: Global Vitiligo Foundation Annual Scientific Symposium; March 16, 2023; New Orleans, LA, USA.

Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. *N Engl J Med*. 2022;387(16):1445-1455. doi:10.1056/NEJMoa2118828

Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. *Pediatr Dermatol*. 2014;31(3):309-18. doi:10.1111/pde.12226



Glossary

BSA, body surface area

CI, confidence interval

F-VASI75, Facial Vitiligo Area Scoring Index

HCP, healthcare professional

OR, odds ratio

QOL, quality of life

RUX, ruxolitinib

SE, standard error

T-VASI50, Total Vitiligo Area Scoring Index

w/, with

yo, year old